Authors
Latest:
Chemotherapy-Free Regimens Gain Ground in Older Patients With ALLWhile there have been exciting advancements in the treatment of B-cell acute lymphoblastic leukemia over the course of the past decade, the treatment of older adults remains a challenge.
Latest:
Building on the Success of Osimertinib in EGFR-Mutated NSCLCSuresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib for the treatment of patients with unresectable stage III non–small cell lung cancer with EGFR mutations.
Latest:
Incorporating Immunotherapy Into Hodgkin Lymphoma Treatment StrategiesStephen M. Ansell, MD, PhD, discusses how immunotherapy is being integrated into treatment for patients with advanced stage Hodgkin lymphoma.
Latest:
Melanoma Monday: A Review of the MSLT-II Trial and Completion Lymph Node DissectionKatherine E. Poruk, MD, reviews the use of complete axillary lymph node dissection and the Multicenter Selective Lymphadenectomy Trial II for Melanoma Monday.
Latest:
Utilizing Interpretable AI to Distinguish prePMF From ETAndrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.
Latest:
Investigating Prognostic Markers for OS With LuPSMA Treatment in mCRPCAndrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.
Latest:
Expanding 177Lutetium-PSMA-617 Use in the CommunityTraining at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Latest:
Choosing the Optimal Treatment for Patients With Prostate CancerNasir Chaudry, MD, discusses treatment decisions for patients with prostate cancer and the importance of individualized treatment based on the specific case and patient preferences.
Latest:
Efficacy and Safety: Brexu-cel's Impact on CNS Response in B-ALLIbrahim N. Muhsen, MD, discusses the findings and key takeaways from his presentation given at the 2024 Tandem Meeting.
Latest:
Expanding Access to Bispecifics in R/R Multiple Myeloma TreatmentIra Zackon, MD, discusses the real-world uptake of bispecific antibodies in community oncology practices and what it reveals about their utilization in relapsed/refractory multiple myeloma treatment.
Latest:
Olanzapine May Help Manage AEs From Tyrosine Kinase InhibitorsOlanzapine may help manage adverse effects from tyrosine kinase inhibitors, though further randomized, placebo-controlled studies are needed to confirm these findings.
Latest:
Next Steps Using Anti-CD19 Therapies in DLBCLThe future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.
Latest:
Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid CancerDuring a Targeted Oncology Case-Based Peer Perspectives event, Andrew G. Gianoukakis, MD, FACE, discussed the use of multikinase inhibitors for RET-mutated medullary thyroid cancer.
Latest:
Further Research Needed to Improve Outcomes in Advanced Ovarian CancerMelissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.
Latest:
Understanding Vorasidenib’s Mechanism of ActionTimothy F. Cloughesy, MD, director of UCLA’s neuro-oncology program and distinguished professor in neurology, discusses the mechanism of action of vorasidenib.
Latest:
Key Takeaways Regarding Use of 45 Gy Novel Radiotherapy in CNS CancersRupesh Kotecha, MD, discusses the key findings from an analysis centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.
Latest:
Roundtable Discussion: Addressing Management of Patients with Metastatic CRPC Following Frontline TreatmentsDuring a Targeted Oncology Case-Based Roundtable event, David I. Quinn, MD, PhD, MBBS leads a discussion on treatment for metastatic castration-resistant prostate cancer following frontline treatment.
Latest:
Future Treatment Approaches for HCCClosing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.
Latest:
Hematology Workforce Shortage Poses Challenges for Cancer CareSrikanth Nagalla, MD, MS, describes initiatives to improve the talent pipeline for hematology staff at all levels.
Latest:
Peterson on Second-Line Ruxolitinib in Acute GVHDPeterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.
Latest:
Immune Checkpoint to Watch: ICOSDeveloping modern strategies to predict and accurately monitor treatment response remains an important piece of the clinical management puzzle.
Latest:
Keeping Track of FGFR Inhibitor AEs Leads to Optimal OutcomesThis article explorex some of the more frequently encountered toxicities of FGFR inhibitors and their optimal management.
Latest:
Gergis Explains the Differences Between Acute and Chronic GVHDUsama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each
Latest:
Findings From the PEACE-1 Trial in mCRPCCedric Pobel, MD, covers the PEACE-1 trial of radiotherapy, standard of care, and abiraterone in low-volume metastatic castration-sensitive prostate cancer.
Latest:
Shining a Light on Sarcoma: Enhancing Awareness for Effective Patient CareAdam C. Berger, MD, FACS, highlights the challenges and advancements in diagnosing and treating sarcoma, a rare and diverse group of cancers originating from mesenchymal tissues.
Latest:
Tailoring Treatments to Better Outcomes in Liver CancerIn season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.
Latest:
The Importance of IMspire150 Data Is Questioned in Melanoma Treatment LandscapeCharles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.
Latest:
Advancing Trials for HER2+ Breast Cancer With Leptomeningeal MetastasisBarbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive breast cancer and leptomeningeal metastasis.
Latest:
Clinical Pearls for Community Oncologists Treating RCCExpert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.
